Please Wait
Applying Filters...
menu
    • menu
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Ibudilast

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Medicinova Advances Brain Metastasis Target From New Study
    Medicinova Advances Brain Metastasis Target From New Study

    27 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/27/3282150/7767/en/new-peer-reviewed-study-reveals-actionable-immune-microenvironment-target-in-brain-metastasis-medicinova-advances-clinical-translation.html

    GLOBENEWSWIRE
    27 Apr 2026
    Share Share
    MediciNova Completes 100-PT SEANOBI EAP for MN-166 (Ibudilast)
    MediciNova Completes 100-PT SEANOBI EAP for MN-166 (Ibudilast)

    29 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/29/3229186/7767/en/MediciNova-Announces-100-Patients-Enrolled-in-SEANOBI-Study-Expanded-Access-Program-EAP-Evaluating-MN-166-ibudilast-in-ALS-patients.html

    GLOBENEWSWIRE
    29 Jan 2026
    Share Share
    MediciNova Completes MN-166 Enrollment in CIPN Prevention Trial
    MediciNova Completes MN-166 Enrollment in CIPN Prevention Trial

    18 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/18/3207535/7767/en/MediciNova-Announces-Completion-of-Patient-Enrollment-Evaluating-MN-166-ibudilast-in-the-Prevention-of-Chemotherapy-induced-Peripheral-Neuropathy.html

    GLOBENEWSWIRE
    18 Dec 2025
    Share Share
    Medicinova Updates MN-166 Phase 2/3 ALS Trial At ALS/MND
    Medicinova Updates MN-166 Phase 2/3 ALS Trial At ALS/MND

    08 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/08/3201345/7767/en/MediciNova-Announces-Update-and-Basic-Characteristic-Randomized-Patients-of-Phase-2-3-Clinical-Trial-of-MN-166-Ibudilast-in-ALS-COMBAT-ALS-Clinical-Trial-Presented-at-the-36th-Inte.html

    GLOBENEWSWIRE
    08 Dec 2025
    Share Share
    MediciNova Wins R&D Innovation Award at 2025 Biotech Awards
    MediciNova Wins R&D Innovation Award at 2025 Biotech Awards

    06 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/06/3183302/7767/en/MediciNova-Wins-Contract-Research-and-Development-Innovation-Award-at-2025-BioTech-Breakthrough-Awards.html

    GLOBENEWSWIRE
    06 Nov 2025
    Share Share
    Medicinova Completes Patient Enrollment In Combat-Als Trial
    Medicinova Completes Patient Enrollment In Combat-Als Trial

    22 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/22/3153885/7767/en/MediciNova-Announces-Completion-of-Patient-Enrollment-in-COMBAT-ALS-Phase-2b-3-Clinical-Trial-of-MN-166-ibudilast.html

    GLOBENEWSWIRE
    22 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.